如果按照规定使用和储存,则不会发生分解,也不存在已知的危险反应。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(4-甲酰基-2-甲氧基苯氧基)乙酸 | (4-formyl-2-methoxyphenoxy)acetic acid | 1660-19-1 | C10H10O5 | 210.186 |
—— | Ethyl 2-[4-(hydroxyiminomethyl)-2-methoxyphenoxy]acetate | 932796-56-0 | C12H15NO5 | 253.255 |
香草醛 | vanillin | 121-33-5 | C8H8O3 | 152.15 |
香草乙酮 | 1-(3-methoxy-4-hydroxyphenyl)ethanone | 498-02-2 | C9H10O3 | 166.177 |
1-(4-苄氧基-3-甲氧基-苯基)-2-(2-甲氧基-苯氧基)-乙酮 | 1-(4-(benzyloxy)-3-methoxyphenyl)-2-(2-methoxyphenoxy)ethan-1-one | 22317-29-9 | C23H22O5 | 378.425 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(4-甲酰基-2-甲氧基苯氧基)乙酸 | (4-formyl-2-methoxyphenoxy)acetic acid | 1660-19-1 | C10H10O5 | 210.186 |
4-(2-羟乙氧基)-3-甲氧基苯甲醛 | 4-(2-hydroxyethoxy)-3-methoxybenzaldehyde | 64673-04-7 | C10H12O4 | 196.203 |
4-羧基甲氧基-3-甲氧基-苯甲酸 | (Carboxymethyl)vanillinsaeure | 19345-44-9 | C10H10O6 | 226.186 |
—— | ethyl 2-(2-methoxy-4-(prop-1-enyl)phenoxy)acetate | 632290-89-2 | C14H18O4 | 250.295 |
—— | Ethyl [2-methoxy-4-(1-propen-1-yl)phenoxy]acetate | 1395081-54-5 | C14H18O4 | 250.295 |
—— | 2-(4-formyl-2-methoxyphenoxy)-N,N-dimethylacetamide | 91641-85-9 | C12H15NO4 | 237.255 |
(2-甲氧基-4-丙烯基苯氧基)-乙酸 | (E)-2-(2-methoxy-4-(prop-1-enyl)phenoxy)acetic acid | 7510-46-5 | C12H14O4 | 222.241 |
—— | ethyl [4-(1,3-dioxolan-2-yl)-2-methoxyphenoxy]acetate | 72676-98-3 | C14H18O6 | 282.293 |
—— | 2-(4-(hydroxymethyl)-2-methoxyphenoxy)ethanol | 936478-21-6 | C10H14O4 | 198.219 |
—— | 1-(3-methoxy-4-hydroxyphenyl)-7-(4-oxoacetoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione | 1347750-39-3 | C23H22O8 | 426.423 |
In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is two-fold; it aimed first at studying the effect of replacing the 5-methylfuryl moiety of the well-known antiangiogenic 2-furylbenzimidazoles with an isopropyl moiety on the VEGFR-2 inhibitory activity and the cytotoxic activity. Our second objective was to further optimize the structures of the benzimidazole derivatives through elongation of the side chains at their one-position for the design of more potent type II-like VEGFR-2 inhibitors. The designed 1,2-disubstituted benzimidazoles demonstrated potent cytotoxic activity against the HepG2 cell line, reaching IC50 = 1.98 μM in comparison to sorafenib (IC50 = 10.99 μM). In addition, the synthesized compounds revealed promising VEGFR-2 inhibitory activity in the HepG2 cell line, e.g., compounds 17a and 6 showed 82% and 80% inhibition, respectively, in comparison to sorafenib (% inhibition = 92%). Studying the effect of 17a on the HepG2 cell cycle demonstrated that 17a arrested the cell cycle at the G2/M phase and induced a dose-dependent apoptotic effect. Molecular docking studies of the synthesized 1,2-disubstituted benzimidazoles in the VEGFR-2 active site displayed their ability to accomplish the essential hydrogen bonding and hydrophobic interactions for optimum inhibitory activity.